A new study shows that a real-world care pathway for patients with NAFLD in primary care can increase the detection of patients with clinically significant liver disease and decrease referrals for patients who could be managed in the community.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
Estes, C. et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).
Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397 (2015).
Patel, P. J. et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern. Med. J. 48, 144–151 (2018).
Alexander, M. et al. Real-world data reveal a diagnostic gap in non alcoholic fatty liver disease. BMC Med. 16, 130 (2018).
Williams, R. et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384, 1953–1997 (2014).
Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. https://doi.org/10.1016/j.jhep.2019.03.033 (2019).
McPherson, S. et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59, 1265–1269 (2010).
Parkes, J. et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 59, 1245–1251 (2010).
Irvine, K. M. et al. The enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int. 36, 370–377 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.E.P. received an unrestricted educational grant from Siemens Healthineers in 2016. P.C.V. declares no competing interests.
Rights and permissions
About this article
Cite this article
Valery, P.C., Powell, E.E. Engaging primary care clinicians in the assessment of NAFLD. Nat Rev Gastroenterol Hepatol 16, 458–460 (2019). https://doi.org/10.1038/s41575-019-0164-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0164-4
